Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orgenesis's annualized net income attributable to common stockholders for the quarter that ended in Dec. 2021 was $-20.06 Mil. Orgenesis's average shareholder tangible equity for the quarter that ended in Dec. 2021 was $20.45 Mil. Therefore, Orgenesis's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 was -98.11%.
The historical rank and industry rank for Orgenesis's Return-on-Tangible-Equity or its related term are showing as below:
ORGS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -73.57 Med: -14.5 Max: 44.58
Current: -66.71
During the past 13 years, Orgenesis's highest Return-on-Tangible-Equity was 44.58%. The lowest was -73.57%. And the median was -14.50%.
ORGS's Return-on-Tangible-Equity is ranked worse than 66.31% of 1389
companies
in the Biotechnology industry
Industry Median: -40.89
vs ORGS: -66.71
Orgenesis Return-on-Tangible-Equity Historical Data
The historical data trend for Orgenesis's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Return-on-Tangible-Equity
-
-
-
44.58
-73.57
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Return-on-Tangible-Equity
-298.20
-2.73
-33.45
-153.44
-98.11
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Return-on-Tangible-Equity Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orgenesis's Return-on-Tangible-Equity falls into.
Orgenesis Return-on-Tangible-Equity Calculation
Orgenesis's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income attributable to common stockholders data used here is four times the quarterly (Dec. 2021) net income attributable to common stockholders data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net income attributable to common stockholders is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orgenesis Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Orgenesis's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.25(11.9%) Volume: 130,258 9:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
